Knockdown of CD51 in PSCs impedes the tumor stroma and reduces cancer cell proliferation, suggesting CD51 as a potential therapeutic target for the pancreatic carcinoma (61). The gene discussed is ITGAV; the disease is exocrine pancreatic carcinoma.